The WHO define GS as an IDH-wildtype astrocytoma and in keeping with this we saw no mutations in IDH1 in GS in our series (vs. 87/1047, 8.3%, in GB). This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).